Tagrisso (osimertinib) / AstraZeneca - LARVOL DELTA

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. (PubMed, N Engl J Med) - P3 | "Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.)."

Journal • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • EGFR

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-year Overall Survival Landmark Update (IASLC-WCLC 2026) - P3 | "Conclusions : This exploratory analysis of ADAURA reports the longest OS follow-up from any adjuvant global Phase III trial in the EGFR-mutated NSCLC setting. These additional long-term results further characterize the established survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated stage IB-IIIA NSCLC, with or without adjuvant chemotherapy."

Clinical • Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821) (IASLC-WCLC 2026) - P2 | "A one-group chi-square test (one-sided alpha = 0.10) had 80% power to detect improvement from 50% (historical osimertinib - standard therapy when AMIGO-1 was designed) to 65% with 49 pts. Toxicity may have limited overall benefit. These findings support further evaluation of AMI+L+ pemetrexed, especially in poor prognostic pts."

Clinical • P2 data • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Pancreatitis • Solid Tumor • EGFR • TP53

Anti-Tumor Activity of BH-30643, a Novel Macrocyclic EGFR TKI, in Patients With Secondary EGFR Resistance Mutations (IASLC-WCLC 2026) - P1/2 | "Responses were observed across different C797S co-mutations (e.g., exon 19 del, L858R, G719S, T790M) and following different targeted therapies (e.g., osimertinib, afatinib, amivantamab). Conclusions : BH-30643 can achieve clinical and molecular responses in heavily pretreated NSCLC patients with secondary EGFR resistance mutations across diverse molecular contexts, supporting its potential as monotherapy in the treatment of resistance to 3rd-generation EGFR TKIs. Expansion cohort enrollment is ongoing with a focus on C797S-positive resistance."

Clinical • First-in-human • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2 • KRAS • MET

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of VRN110755 in EGFR-Mutated NSCLC (IASLC-WCLC 2026) - "VRN110755 demonstrated dose-proportional PK, and at 320 mg, C trough /IC 50 -based target engagement against common EGFR mutations was approximately 4-fold higher than that observed with osimertinib 80 mg. Particularly, a notable tumor response was observed in the C797S-positive subgroup after prior 3rd-generation EGFR TKI treatment. These data support dose optimization and expansion to define the RP2D and assess POC in groups including C797S-positive patients after third-generation TKI or treatment-naive EGFR-mutated NSCLC with/without brain metastasis."

Clinical • PK/PD data • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • EGFR

Subcutaneous Amivantamab+Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up From the Pragmatic COPERNICUS Study (IASLC-WCLC 2026) - P2 | "Introduction : Intravenous amivantamab plus lazertinib significantly prolonged overall survival versus osimertinib (HR, 0.75; P =0.005) in first-line common EGFR -mutant ( EGFR m) advanced NSCLC in MARIPOSA. Reductions were observed in ARRs, rash, VTE, and AE-associated amivantamab discontinuations, despite an older population than MARIPOSA. These results demonstrate that early supportive care and subcutaneous administration Q4W can improve patient experience of amivantamab plus lazertinib in a clinical practice setting, supporting its broad use as first-line therapy."

Cardiovascular • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Venous Thromboembolism • EGFR

A Phase III Randomized Multicenter Trial of Adjuvant Gefitinib Plus Chemotherapy Versus Chemotherapy in EGFR-Mutant NSCLC (IASLC-WCLC 2026) - "Introduction : Approximately 30% of patients with surgically resected non-small cell lung cancer (NSCLC) experience recurrence. The benefit appeared greater in exon 19 deletion than in L858R disease, with manageable toxicity. In the era of adjuvant osimertinib, longer follow-up and further minimal residual disease (MRD) analyses are warranted to clarify the role of TKI- and/or chemotherapy-based adjuvant treatment."

Clinical • P3 data • Dermatitis • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results (ESMO 2026) - No abstract available

Late-breaking abstract • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem) (ESMO 2026) - No abstract available

Clinical • Clinical data • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

PACE-LUNG: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment (AIO-TRK-0422/ass) (ESMO 2026) - No abstract available

Circulating tumor DNA • Clinical • Late-breaking abstract • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - P1 | N=190 | Active, not recruiting | Sponsor: AstraZeneca | Trial primary completion date: Aug 2028 ➔ Jun 2026

First-in-human • Monotherapy • Trial primary completion date • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov) - P2 | N=68 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Mar 2027 ➔ Sep 2027

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC) (ESMO Asia 2023) - P1/2 | "Conclusions MCLA-129 plus osimertinib showed promising clinical efficacy in EGFRmut NSCLC, in 1L and 2L+. IRRs and ILD/pneumonitis were observed."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. (PubMed, Lung Cancer) - "High PD-L1 expression primarily signals early risk, whereas bone metastasis and high Meta-N are persistent barriers to long-term response durability. Postoperative recurrence is a consistently favorable factor for survival. These findings support risk-adapted therapy; these high-risk subgroups may represent rational candidates for evaluating front-line intensification strategies in prospective clinical trials, whereas osimertinib monotherapy remains appropriate for lower-burden disease, such as postoperative recurrence."

IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-L1

Real-World Evidence on Osimertinib Prescribing Patterns in Non-Small Cell Lung Cancer in a Low-income Country (ESMO 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Reassessing the Incidence and Risk Factors of Radiation Pneumonitis in Treatment-Naive EGFR-Mutant NSCLC with Concurrent Third-Generation EGFR-TKI and Thoracic Radiotherapy (ASTRO 2026) - "Grade =2 RP incidence by TKI was 54.25% (51/94) for osimertinib, 36.36% (32/88) for aumolertinib, and 29.63% (8/27) for furmonertinib; grade 3 RP rates were 25.53% (24/94), 20.45% (18/88), and 11.11% (3/27), respectively. First-line third-generation EGFR-TKI plus TRT showed no grade 4–5 RP. RP risk was independently associated with TKI selection, ipsilateral lung V5/V30, and GTV. Risk appeared to increase when ipsilateral lung V5 exceeded approximately 35% and when V30 exceeded approximately 25% (data-driven thresholds), together with larger GTV."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase II Trial of Biology Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) in Oligoprogressive Non-Small Cell Lung Cancer: Interim Report (ASTRO 2026) - P2 | "The majority of patients (n=8) had EGFR mutant NSCLC and were treated with osimertinib... Utilization of SBRT/BgRT in oligoprogressive NSCLC appears to provide some delay to next line systemic therapy. Continued accrual, data maturation, and toxicity monitoring, in addition to quality of life and biomarker correlatives including ctDNA, which are currently being collected, will provide further insight to the potential benefit of LAT for this patient population."

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

FLAURARE – Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) (ESMO 2026) - No abstract available

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Real-world (rw) clinical outcomes with second-line (2L) osimertinib (osi) + platinum-based chemotherapy (CTx) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC and progression on first-line (1L) osi (ESMO 2026) - No abstract available

Clinical • Clinical data • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Characterization and Molecularly Matched Treatment of EGFR-Positive NSCLCs Acquiring the C797S Mutation After 1st Line Osimertinib: Real-World Data from the ATLAS Database. (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Access to Re-Biopsy and Subsequent Therapy After Osimertinib in EGFR-Mutated NSCLC: A Single-Center Experience from Argentina (ESMO 2026) - No abstract available

Biopsy • Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Telisotuzumab vedotin endolysosomal trafficking is enhanced with osimertinib co-treatment in EGFRmut NSCLC (ESMO 2026) - No abstract available

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patterns of Brain Relapse Following First-Line Osimertinib in EGFR-Mutant Non–Small Cell Lung Cancer With Brain Metastases (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Real-World Outcomes, Resistance Patterns, and Access Disparities in EGFR-Mutant NSCLC Treated With Osimertinib: A Multicenter Argentine Study. GAOT - EGFR-01. (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR